¹ Meta-analysis of genotype-phenotype

² associations in Alström syndrome.

- 3
- 4 Brais Bea-Mascato^{1,2}, Diana Valverde^{1,2*}
- 5
- 6 ¹ CINBIO, Universidad de Vigo, 36310, Spain.
- 7 ² Grupo de Investigación en Enfermedades Raras y Medicina Pediátrica, Instituto de
- 8 Investigación Sanitaria Galicia Sur (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
- 9
- 10 *Correspondence: Diana Valverde
- 11 CINBIO Facultad de Biología, Universidad de Vigo, Campus As Lagoas-Marcosende s/n,
- 12 36310 Vigo, Spain
- 13 Tel +34 986 811 953
- 14 Email dianaval@uvigo.es

15

16

17 Abstract:

18 Introduction: Alström syndrome (ALMS, #203800) is an ultra-rare monogenic recessive 19 disease. This the syndrome is associated with mutations in the ALMS1 gene, which codes 20 for a centrosome structural protein responsible for centrosome cohesion. The type of 21 mutation associated with ALMS is mostly cLOF (97%) and they are mainly located in 22 exons 8, 10 and 16 of the gene. Other studies in the literature have tried to establish a 23 genotype-phenotype correlation in this syndrome with little success. The difficulty in 24 recruiting a large cohort in rare diseases is the main barrier to conducting this type of 25 study.

Methods: In this study we have collected all cases published to date for ALMS. We have created a database with those patients who had a genetic diagnosis and an individualised clinical history. Finally, we have attempted to establish a genotypephenotype correlation using the truncation site of the patient's longest allele as a grouping criterion.

Results: We collected a total of 357 patients of which 227 had complete clinical information, complete genetic diagnosis and meta information regarding sex and age. We have seen that there are 5 variants in high frequency with p.(Arg2722Ter) being the most common variant with 28 alleles. There are no gender differences in disease progression. Finally, truncating mutations in exon 10 seem to be correlated with a higher prevalence of liver disorders in patients with ALMS.

37 Conclusion: The location of the mutation in the *ALMS1* gene does not have a major
38 impact on the phenotype developed by the patient. Only mutations in exon 10 of the
39 *ALMS1* gene were associated with a higher prevalence of liver disease.

40

41 Keywords: ALMS, Alström syndrome, ciliopathy, genotype-phenotype, metabolic
42 disease, obesity, meta-analysis, rare disease.

43

44 Introduction:

Alström syndrome (ALMS, #203800) is an ultrarare monogenic disease caused by
mutations in the *ALMS1* gene. It is an autosomal recessive disorder with an estimated
incidence of 1-9 cases per-1,000,000 inhabitants and currently there are an estimated
1000 cases described worldwide (Orphanet; 03-05-2022).

49 Most of mutations associated with this disease are complete loss-of-function (cLOF) 50 mutations that generate a stop codon either at the same site as the mutation or result 51 in a frameshift alteration leading to a stop codon (Marshall et al., 2015). There are 52 currently 388 loss-of-function variants reported in ClinVar and 253 in gnomAD. These 53 pathogenic variants have a uniform distribution along the gene and are mainly located 54 in coding regions. Whole exome sequencing (WEG) is a standard practice for the genetic 55 testing of rare diseases, which implies that intronic regions are poorly studied, 56 explaining why most pathogenic variants are detected in coding regions (Sawyer et al., 57 2016). Exons 8, 10 and 16 are considered mutation hotspots, but this seems to be due 58 to their large size rather than a specific regulatory correlation. Exon 8 (6,108bp) for 59 example covers 50% of the total gene sequence (12,844bp).

60 ALMS presents a very heterogeneous phenotype in which symptoms can be aggregates 61 into two main groups (Marshall et al., 2007a, 2011). A first group includes the presence 62 of retinal dystrophy from early life, various metabolic disorders (obesity, hypertriglyceridemia or type 2 diabetes mellitus), hearing loss, liver and kidney 63 dysfunction and cardiac disorders such as dilated cardiomyopathy (DCM) (Marshall et 64 al., 2005, 2007b, 2007a). The second group of symptoms would include short stature, 65 66 recurrent pulmonary infections, mental and cognitive impairment and various 67 endocrine disorders affecting the thyroid and reproductive system (Marshall et al., 68 2007a). This second group would also include other very rare symptoms, such as 69 alterations in the fingers, alopecia and spinal abnormalities (Marshall et al., 2007a).

ALMS is characterised by high intra- and inter-familial phenotypic heterogeneity (Marshall et al., 2005, 2007a, 2007b, 2011). This means that siblings with the same genotype may have different phenotypes, which complicates the establishment of a genotype-phenotype correlation (Hollander et al., 2017).

Several studies have attempted to establish a genotype-phenotype correlation without success using cohorts with 12-18 patients (Bond et al., 2005; Minton et al., 2006). Studies in larger cohorts, 58 patients, have shown that there is correlation between disease-causing variants in exon 16 and the presence of retinal degeneration before one year of age , the occurrence of urological dysfunction, DCM and diabetes (Marshall et al., 2007b). Moreover, this study found a significant correlation between diseasecausing variants in exon 8 and the absent, mild or delayed kidney disease.

81 Premature termination codon (PTC) mutations are often classified as cLOF and are 82 associated with the activation of nonsense-mediated mRNA decay (NMD), which results 83 in the elimination of the expression of the mutated gene (Supek et al., 2021). However, 84 it has been shown that NMD is not 100% efficient when nonsense mutations are located in the last exons of genes (Kerr et al., 2001; Lindeboom et al., 2016; Supek et al., 2021). 85 86 In the case of ALMS, there are patients who continue to express the ALMS1 protein even 87 when carrying two cLOF variants (Chen et al., 2017). In that study of 23 patients where 88 the clinical manifestations were related to the expression or non-expression of the 89 ALMS1 gene, it was observed that those patients with residual ALMS1 gene expression 90 presented milder phenotypes (Chen et al., 2017).

91 Although there are several databases that list the mutations described in the ALMS1 92 gene (GnomAD, ClinVar), only one, LOVD, offers a register with 140 patients but the 93 clinical data is absent or incomplete in many cases (Fokkema et al., 2011; Landrum et 94 al., 2018; Karczewski et al., 2020). There is still no open patient registry that collects 95 clinical and genetic information in a comprehensive way. In this study, we have reviewed 96 112 publications related to ALMS and compiled all available clinical and genetic 97 information. We have collected a total of 357 patients, manually curated, on which various analyses have been performed to look for a genotype-phenotype correlation. 98 99 Finally, we have made this dataset available to the scientific community in a single public 100 access database (<u>http://genesandfunctions.uvigo.es/alms-db/</u>).

101

102 Methods:

¹⁰³ Preferred reporting items for systematic reviews and

¹⁰⁴ meta-analyses (PRISMA) guidelines:

This meta-analysis was performed following the PRISMA guidelines, as described in Niederlova et al. (Niederlova et al., 2019), for Bardet Biedl syndrome (BBS). In this case, the main PICO question our study sought to address was: Do ALMS patients have different phenotypes depending on where in the gene, the stop mutation occurs?. Similar studies have been conducted in smaller cohorts grouping patients by major mutational hotspots in the *ALMS1* gene. (Marshall et al., 2005, 2007b; Astuti et al., 2017).

¹¹² Search strategy:

113 The PubMed and Google Scholar databases were searched in January 2022 using the following keyword combination: ("Alström syndrome" OR ALMS) AND ("genotype 114 115 phenotype" OR "cohort" OR "case report"). The screening of the search results was 116 carried out by BB-M by initially examining the title and abstract to determine whether it 117 corresponded to the subject of the analysis. Some of the articles analysed in this study 118 were not initially found by the database search but were detected by the 119 recommendations and bibliography of other more relevant works. The search was 120 conducted in English only, covering a period between the origin of the databases and 121 the date of the search (January 2022).

122 Study selection:

All articles selected in a first search were carefully reviewed to meet the criteria for inclusion in the meta-analysis. After a thorough reading of the article, the study was included if the following characteristics were met: the cohort of the article included a patient with a diagnosis of ALMS, and the diagnosis had a genetic and clinical characterisation. Articles whose diagnosis of ALMS was based solely on phenotype were

128 discarded, (Charles et al., 1990; Holder et al., 1995; Russell-Eggitt et al., 1998; Koray et 129 al., 2001; Worthley and Zeitz, 2001; Benso et al., 2002; Satman et al., 2002; Paisey et al., 130 2004; Hoffman et al., 2005; Hamamy et al., 2006; Koç et al., 2006; Gogi et al., 2007; Silan 131 et al., 2013; Bronson et al., 2015; Boerwinkle et al., 2017; Davies et al., 2018), as well as 132 those that simply presented or reported the patient's mutations without giving an 133 complete (Lazar et al., 2015) or individualised clinical history (Patel et al., 2006; Marshall 134 et al., 2007b, 2015; Redin et al., 2012; Kilpinen et al., 2017; Gao et al., 2019; Baig et al., 135 2020). From an initial selection of 108 studies, 31 (Millay et al., 1986; Charles et al., 1990; 136 Holder et al., 1995; Russell-Eggitt et al., 1998; Koray et al., 2001; Worthley and Zeitz, 137 2001; Benso et al., 2002; Satman et al., 2002; Wu et al., 2003; Iannello et al., 2004; Paisey 138 et al., 2004; Hoffman et al., 2005; Marshall et al., 2005, 2007b, 2015; Koç et al., 2006; 139 Patel et al., 2006; Hamamy et al., 2006; Gogi et al., 2007; Hitz et al., 2008; Catrinoiu et 140 al., 2009; Redin et al., 2012; Silan et al., 2013; Lazar et al., 2015; Bronson et al., 2015; 141 Ahmad et al., 2016; Huang et al., 2016; Lindsey et al., 2017; Boerwinkle et al., 2017; Gao 142 et al., 2019; Baig et al., 2020) were discarded and 76 (Titomanlio et al., 2004; Bond et 143 al., 2005; Minton et al., 2006; Joy et al., 2007; Özgül et al., 2007; Malm et al., 2008; 144 Aldahmesh et al., 2009; Khoo et al., 2009; Liu et al., 2009; Kocova et al., 2011; Wang et 145 al., 2011, 2016a, 2016b, 2021; Aliferis et al., 2012; Jatti et al., 2012; Piñeiro-Gallego et 146 al., 2012; Taokesen et al., 2012; Corbetti et al., 2013; Katagiri et al., 2013; Kuburović et 147 al., 2013; Liang et al., 2013; Mahamid et al., 2013; Taşdemir et al., 2013; Kaya et al., 2014; Bahmad et al., 2014; Louw et al., 2014; Ozantürk et al., 2014; Sanyoura et al., 148 149 2014; Casey et al., 2014; Khan et al., 2015; Kim et al., 2015; Long et al., 2015; Sathya 150 Priya et al., 2015; Chakroun et al., 2016; Laxer et al., 2016; Nikopoulos et al., 2016; Xu et 151 al., 2016; Zmyslowska et al., 2016; Chen et al., 2017; Cruz-Aguilar et al., 2017; Das 152 Bhowmik et al., 2017; Hollander et al., 2017; Astuti et al., 2017; Jinda et al., 2017; Bakar 153 et al., 2017; Wicher et al., 2017; Brofferio et al., 2017; Yang et al., 2017; Castro-Sánchez 154 et al., 2017; Dotan et al., 2018; Kilinc et al., 2018; Kvarnung et al., 2018; Maltese et al., 155 2018; Nasser et al., 2018; Sanchez-Navarro et al., 2018; Tsai et al., 2018; Waldman et al., 156 2018; Shurygina et al., 2019; Weiss et al., 2019; Gatticchi et al., 2020; Hirano et al., 2020; 157 Hull et al., 2020; Kamal et al., 2020; Lombardo et al., 2020; Mauring et al., 2020; 158 Rethanavelu et al., 2020; Spinelli et al., 2020; Torkamandi et al., 2020; Zhou et al., 2020;

159 Bea-Mascato et al., 2021; Saadah et al., 2021; Srikrupa et al., 2021; Zhang et al., 2021)

160 were selected for information extraction and subsequent analyses.

¹⁶¹ Data extraction and curation:

162 For the extraction of information, three main groups were defined: metadata, genetic

163 information, and clinical information.

The metadata refers to the: ID of each patient within the dataset, the ID of the family to which they belong (patients with the same family ID are siblings) and the reference from where the information of that patient has been extracted.

167 In the case of genetic information, whenever possible, the following should be 168 extracted: the original allele reference, the nomenclature of the mutation for the cDNA 169 and protein sequence, the exon/intron where the mutation is located and the genotype 170 of the patient (homozygote or compound heterozygote). All reported mutations were 171 named following the HGVS guidelines with the transcript NM 015120.4 and validated 172 with the name checker of the mutalyzer software (Lefter et al., 2021). The back 173 translator tool of the mutalyzer software was also used to determine the mutation 174 nomenclature at the cDNA level when only the protein annotation of the mutation was 175 provided in the article. In these cases, only nonsense and stop mutations could be 176 determined, as the algorithm does not work with frameshift mutations.

177 With regard to the clinical information, sex, age and ethnicity were extracted (whenever 178 possible), the diagnostic criteria named by Marshall et al., (Marshall et al., 2007a) were 179 used to try to homogenise it: vision impairments (history of nystagmus in infancy/childhood, legal blindness, cone and rod dystrophy by ERG); obesity and/or 180 181 insulin resistance and/or T2DM; history of DCM/CHF; hearing loss; hepatic disfunction; 182 renal failure; pulmonary dysfunction; short stature; males: hypogonadism; females: 183 irregular menses and/or hyperandrogenism; thyroid disorders; mental retarded; 184 abnormal appearance of a finger, Intestinal problems, scoliosis/flat wide feet, epilepsy 185 and alopecia (Table 1). Initially, the full information reported in the article was noted for 186 each individual symptom and the age of onset if this was reported. This was then 187 converted into a binary matrix to simplify and homogenise the subsequent analysis.

Table 1. Abbreviations used in the analysis, full name of the phenotypic categories, phenotypes aggregated in each category, prevalence of each phenotypic
 category in the study cohort and representative HPO terms for each category.

Abbrev.	Complete name	Phenotype	Prevalence (%)	HPO terms added in each category
VI	Vision impairments	History of nystagmus in infancy/childhood, legal blindness, cone and rod dystrophy by ERG	96.54	HP:0000556 (Retinal dystrophy) HP:0000639 (Nystagmus) HP:0000618 (Blindness)
MT	Metabolic anomalies	Obesity and/or insulin resistance and/or Type 2I diabetes mellitus (T2DM)	85.88	HP:0001513 (Obesity) HP:0005978 (T2DM)
HL	Hearing anomalies	Hearing loss	62.54	HP:0000365 (Hearing loss)
HRT	Heart anomalies	History of Dilated cardiomyopathy/congestive heart failure (DCM/CHF)	49.86	HP:0001644 (DCM) HP:0001635 (CHF)
LIV	Liver anomalies	Hepatic dysfunction	34.58	HP:0001410 (Decreased liver function)
REN	Renal anomalies	Renal failure	29,68	HP:0000077 (Renal anomaly)
MEND	Mental anomalies	Mental disability	22.48	HP:0001249 (Intellectual disability)
REP	Reproductive system anomalies	Males: hypogonadism; Females: irregular menses and/or hyperandrogenism	15.56	HP:0000026 (Male hypogonadism) HP:0000858 (Irregular menstruation)
PUL	Pulmonary anomalies	Pulmonary dysfunction	14.99	HP:0002795 (Impaired pulmonary function)
SCO	Spine/feet anomalies	Scoliosis/flat wide feet	14.12	HP:0002650 (Scoliosis) HP:0001763 (Pes planus)
TYD	Thyroid metabolism anomalies	Thyroid disorders	11.53	HP:0000820 (Abnormality of the thyroid gland)
SHS	Stature anomalies	Short stature	7.78	HP:0004322 (Short stature)
ALO	Alopecia	Alopecia	4.61	HP:0001596 (Alopecia)
NER	Nervous system anomalies	Epilepsy	3.75	HP:0001250 (Seizure)
ABFING	Finger anomalies	Abnormal appearance of a finger	1.15	HP:0001155 (Abnormality of the hand)
INT	Intestine anomalies	Intestinal problems	1.15	HP:0011024 (Abnormality of the gastrointestinal tract)

190

¹⁹¹ Statistical frequency analysis:

192 To determine the existence of a genotype-phenotype correlation in our patient registry, 193 we selected a sub-cohort of 227 patients who met the following criteria: I) complete 194 genetic information (Detection of two mutated alleles with complete notation at the 195 cDNA and protein level), II) complete clinical information (Sex, age and presence or 196 absence of the 5 most prevalent clinical manifestations used in these patients: vision impairments, metabolic anomalies, hearing anomalies, heart anomalies and liver 197 198 anomalies). The heterogeneity of the clinical notation associated with these 5 categories 199 was summarised in a binary matrix (1=presence, 0=absence) which was used for 200 frequency calculations to determine the prevalence of each symptom in the cohort and 201 the different subgroups.

Following the methodology described by Niederlova et al., (Niederlova et al., 2019) a syndromic score between 0 and 1 was calculated. This syndromic score gives an estimate of how many of the 5 most prevalent clinical manifestations described above are present in each patient.

In this study the lack of race was not considered to exclude a patient from being included
in the study cohort. Due to the high heterogeneity of this characteristic and the small
cohort size, correlations with enough statistical power could not be established.

Patient ages were initially aggregated into 10-year age intervals: 0-9, 10-19, 20-29, 3039, 40-49, 50-59. After studying the evolution of the syndromic score in the different
age intervals, it was found that the number of patients above 39 years was very small.
This is consistent with the life expectancy of patients with ALMS, which is usually not
more than 50 years. For this reason, a regrouping of the last 3 intervals in patients over
30 years of age was made for the subgroup analysis.

Following the methodology used by Marshall et al., (Marshall et al., 2007b) patients were genotypically grouped according to the different mutational hotspots: exon 8 (E8), exon 10 (E10) and exon 16 (E16). For compound heterozygous patients this aggregation was performed based on the patient's longest allele. Since ALMS is an autosomal recessive disease, it is expected that a single functional copy of the gene is sufficient to

prevent the appearance of the symptoms of the disease (Collin et al., 2002; Hearn,
2018). In this way, it would be expected that a protein truncated in exon 16-20 could
have more possibilities of maintaining a certain functionality than if it is truncated in
exon 5.

Approximately 90% of the mutations were found in the mutation hotspots (E8, E10, and E16), but to include the remaining % in the study, 3 intervals were defined: longest allele truncated before exon 9 (E8), longest allele truncated between exon 9 and 14 (E10), longest allele truncated after exon 14 (E16).

In cases where only two groups were compared, a Wilcoxon test was used. In trials where comparisons were made between several groups (more than 2), an overall pvalue calculation was performed using the non-parametric Kruskal-Wallis test, followed by a comparison of means by groups of two using the Wilcoxon test with correction for FDR, with corrected p-values of less than 0.05 being considered significant.

For the analysis of the prevalence of symptoms in the different genetic groups, contingency tables were created showing the number of positive/negative cases within each patient group. Differences in the prevalence of phenotypes in the different patient groups were assessed using pairwise Fisher's exact test. Statistical significance of differences between individual groups was determined with the FDR correction for multiple comparisons.

239 **Results:**

240 Cohort description:



Figure 1. Cohort Description of 227 ALMS patients. (A) Counting of the different alleles in the cohort. Alleles with more than 2 copies in the cohort are represented. (B) Number of alleles per exon in the study cohort. (C) Patients grouped by their copy of the *ALMS1* gene with the later truncation mutation. (D) Age composition in the subgroups with the latest truncation site in the *ALMS1* gene in exon 8 (E8), exon 10 (E10) and exon 16 (E16).

247 A total of 357 patients were collected from a total of 76 scientific publications that 248 passed the initial screening. Only patients with information on sex, age and a complete 249 genetic characterisation (description of two non-functional alleles; methods) were used 250 for further analysis. Only mutations in coding regions were considered in the study. This 251 reduced the initial cohort to a total of 227 patients, 128 (56.38%) males and 99 females 252 (43.61%). This study cohort contained a total of 176 variants where 168 were cLOF and 253 8 missense mutations (Figure S1). Most of them were private mutations, but 5 254 mutations were shown to have a high frequency: p.(Arg2722Ter) (28 alleles), p.(Gln3495Ter) (22 alleles), p.(Thr3592LysfsTer6) (14 alleles), p.(Glu3773TrpfsTer18) (11 255 256 alleles) and p.(Pro3911GInfsTer16) (10 alleles) (Figure 1A). The number of alleles

257 described for these mutations shows certain inconsistencies with the gnomAD database

and in some cases the variant does not even appear in gnomAD database (Table 2).

- 259 **Table 2.** Differences in the number of alleles reported in gnomAD and in our database for the
- 260 most recurrent mutations.
- 261

Pathogenic variant	ALMSDB	gnomAD
p.(Arg2722Ter)/p.(Arg2720Ter)	28	4
p.(Gln3495Ter)/p.(Gln3493Ter)	22	11
p.(Thr3592LysfsTer6)/p.(Thr3590LysfsTer6)	14	14
p.(Glu3773TrpfsTer18)/p.(Glu3771TrpfsTer18)	11	6
p.(Pro3911GInfsTer16)	10	0

262

Patients were initially grouped into age ranges by decades (from 0 to 59 years) but due
to the low number of patients in the age ranges 40-49 and 50-59 years, they were added
to the 30-39 years group and reclassified as over 30 years for further analysis.

Out of a total of 454 alleles, 207 (45.59%) were in exon 8, 107 (23.57%) in exon 16 and 81 (17.84%) in exon 10 **(Figure 1B)**. Making these exons the main mutation hotspots in our cohort, consistent with the literature.

Due to the recessive nature of ALMS, we decided to define the characteristic allele of each patient according to the mutation furthest from the origin of the gene (Figure 1C). Many of the patients carrying mutations in exon 8 were compound heterozygotes with mutations in exon 16. After this regrouping we saw that 80 (35.34%) patients had the largest allele truncated in exon 8, 42 (18.50%) in exon 10 and 75 (33.03%) in exon 16.

274 In accordance with other similar study (Marshall et al., 2007b) we used the mutation 275 hotspots (exons 8, 10 and 16) to subdivide the patients into genetic groups E8, E10 and 276 E16 respectively. Due to the low frequency of mutations in other exons of the ALMS1 277 gene we decided to add patients with truncated alleles in adjacent exons to these 278 mutation hotspots. Group E8 includes all patients with the longest truncated allele 279 before exon 9. Group E10 includes patients with the longest truncated allele between 280 exon 9 and exon 13. Finally group E16 included patients with the longest truncated allele 281 from exon 14 to exon 20. As a result, groups E8, E10 and E16 contained 85, 45 and 97 282 patients respectively (Figure 1D).

Patients with mutations in exon 10 have a higher 283 syndromic score than the other subgroups: 284

For the strategy of collecting phenotypic manifestations, 16 syndromic groups 285 286 (methods) were initially defined. In the genotype-phenotype correlation analysis, a minimum prevalence threshold of 15% (n=33) was established in the cohort (Figure S2). 287 288 This reduced the initial phenotypic manifestations to 9 groups: visual impairments (VI, 289 97.80%), metabolic anomalies (MT, 85.02%), hearing anomalies (HL, 59.91%), heart anomalies (HRT, 49.34%), liver anomalies (LIV, 36.56%), renal anomalies (REN, 29.52%), 290 291 mental anomalies (MEND, 24.67%), reproductive system anomalies (REP, 17.62%), 292 pulmonary anomalies (RES, 19.38%).

293 Following the methodology developed by Niederlova et al., (Niederlova et al., 2019), the 294 5 main disease conditions (VI, MT, HL, HRT and LIV; methods) were used to create a 295 discrete syndromic score ranging from 0 to 1 (Figure 2A). The mean of this syndromic 296 score in the total cohort is around 0.7, with the most common values being 0.6 (3 of the 297 5 symptoms) and 0.8 (4 of the 5 symptoms) (Figure 2B). No significant differences in 298 syndromic score were observed between sexes. However, the syndromic score 299 increased significantly in the different age ranges of the patients (p-value = 3.1 e-10; 300 Figure 2C-D). This is consistent with the progressive worsening that these patients 301 undergo throughout their lives (Marshall et al., 2005, 2007a). Finally, we observed how 302 the syndromic score was distributed in the different groups defined according to their 303 largest transcript. Patients whose longest transcript was truncated around exon 10 (E10) 304 had a higher syndromic score compared to the E8 (p-value = 0.017) and E16 (p-value = 305 0.016) groups (Figure 2E).

medRxiv preprint doi: https://doi.org/10.1101/2022.10.21.22281173; this version posted October 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



306

307 Figure 2. Study of the phenotypic impact on different subgroups of the study cohort. (A) 308 Prevalence of the 5 main phenotypic groups in the cohort: visual impairments (VI), 309 metabolic anomalies (MT), hearing anomalies (HL), heart anomalies (HRT) and liver

- anomalies (LIV). (B) Distribution of syndromic scores calculated from the presence or
- absence of the 5 most relevant phenotypic groups. (C) Gender comparison of syndromic
- 312 scores. (D) Comparison of the syndromic scores between age groups. (E) Comparison of
- 313 the syndromic scores between subgroups created from the longest copy of the *ALMS1*
- 314 gene.
- ³¹⁵ Patients with truncation variants around exon 10
- ³¹⁶ have a higher prevalence of liver disease:



317

Figure 3 Correlation study between symptoms prevalence and the truncation site of the
 ALMS1 gene. (A) Evolution of the syndromic score among the subgroups by the longest

320 copy of the *ALMS1* gene in the different age groups. (B) Prevalence of the different
321 symptom clusters in the subgroups by the longest copy of the *ALMS1* gene.

322 To determine whether the differences between the E8, E10 and E16 groups were due to 323 an unequal composition between the different age ranges in each group, the syndromic 324 score was studied by combining both parameters (age and genetic group) (Figure 3A). 325 In the first decade of life, no significant differences in syndromic score were observed 326 between the groups. Between the ages of 10 to 19 years, a higher syndromic score was 327 observed in the E10 group compared to the E16 group (FDR = 0.061). From 20-29 years 328 of age, a higher syndromic score was observed in the E10 group compared to the E8 and 329 E16 groups (FDR = 0.009, in both cases). Finally, in patients over 30 years of age, no 330 significant differences were observed between the genetic groups.

After concluding that the differences observed between the groups were not due to an unequal age composition between them, the prevalence of the 9 phenotypic manifestations in each of these groups was studied **(Figure 3B)**. Patients within the E10 group were found to have a higher prevalence of liver disorders compared to patients in the E8 and E16 groups. For the remaining 8 syndromic manifestations no significant differences were found between the genetic groups.

Discussion:

338 Meta-analyses are a useful tool to address one of the main limitations when attempting 339 to establish a genotype-phenotype correlation in a rare disease, the inability to recruit 340 a large cohort to draw robust and statistically significant conclusions. Although meta-341 analyses mainly focus on the aggregation of several studies with well-defined and well-342 studied cohorts, this is often not possible in rare diseases. Alternatively, one can try to 343 aggregate information obtained from case reports in the literature. However, the lack 344 of uniform criteria in how authors describe their patients is one of the main biases of 345 this approach. In this paper we adapt and apply the methodology described by 346 Niederlova et al (Niederlova et al., 2019) from a polygenic disease such as BBS to a 347 monogenic disease such as ALMS.

348 Despite the fact that ALMS is a monogenic disease (Hearn et al., 2002), to date several 349 studies have already discussed the possible existence of several tissue-specific isoforms 350 for the ALMS1 gene, which may have different regulatory roles that explain the high 351 symptomatic heterogeneity (Collin et al., 2002, 2012; Hearn et al., 2002; Braune et al., 352 2017). Although this is an interesting approach, the isolated nature of the data published 353 in the case reports does not allow validation it. In order to validate this hypothesis, the 354 recruitment of a large cohort is necessary. Different cohorts have been described in the 355 literature, the largest being Marshall et al. (Marshall et al., 2007b), followed by Ozantürk 356 et al. (Ozantürk et al., 2014), the NIH clinical centre cohort (Brofferio et al., 2017; 357 Waldman et al., 2018), Chen et al. (Chen et al., 2017) and Rethanavelu et al. 358 (Rethanavelu et al., 2020) with 58, 44, 38, 23 and 21 ALMS patients, respectively. 359 Significant genotype-phenotype correlations were only detected in Marshall et al 360 (Marshall et al., 2007b), highlighting the importance of the sample size used in this type 361 of study.

362 The causal mutations of ALMS are mainly of the cLOF type (generating a PTC) (Marshall 363 et al., 2015). These types of mutations activate nonsense-mediated decay (NMD), 364 preventing the translation of the sequence from mRNA to protein (Supek et al., 2021). 365 However, certain situations have been described, such as PTC mutations in the last 366 exons of a gene, in which NMD can be prevented or incompletely produced (Lindeboom 367 et al., 2016; Supek et al., 2021). Chen et al., have detected ALMS1 gene expression in 368 patients carrying two cLOF mutations leading to PTC (Chen et al., 2017). That study has 369 also correlated residual ALMS1 gene expression with the development of milder 370 phenotypes (Chen et al., 2017). Taking this into account, it could happen that cLOF 371 mutations in the terminal exons of the ALMS1 gene do not activate NMD, generating a 372 partially functional protein or a non-functional misfolded protein. Under this hypothesis, 373 we grouped the patients in our study according to the longest transcript they had. Three 374 different groups related to the main mutational hotspots of the ALMS1 gene, exons 8, 375 10 and 16, were defined. A similar approach has already been used on a cohort of 58 376 ALMS patients by Marshall et al. (Marshall et al., 2007b). Subsequently, a syndromic 377 score was created by adding the 5 clinical manifestations more prevalent of ALMS. This 378 methodology was adapted from Niederlova et al, (Niederlova et al., 2019).

379 The results showed that the syndromic score increases with age (Figure 2D), which was 380 consistent with the gradual worsening that these patients suffer throughout their lives 381 (Marshall et al., 2005, 2007a). This helped us to validate the effectiveness of the 382 syndromic score in measuring the severity of the patient symptoms. When comparing 383 the syndromic scores of the different genetic groups by age groups, it was observed that 384 patients with truncation mutations in exon 10 (E10) evolve more unfavourably than the 385 rest (Figure 3A). The fact that these differences are not appreciable after the age of 30 386 years could be due to a higher mortality in this group in the second and third decades of 387 life. This supposed higher mortality after 30 years could be correlated with the greater 388 prevalence of liver problems that patients with truncation mutations at exon 10 (E10) 389 appear to have (Figure 3B). This correlation was not detected in previous genotype-390 phenotype analyses (Bond et al., 2005; Minton et al., 2006; Patel et al., 2006; Marshall 391 et al., 2007b). Marshall et al., (Marshall et al., 2007b) described disease-causing variants 392 in exon 16 as leading to urological dysfunction, DCM and diabetes. In our study, we did 393 not look for correlations in urological dysfunction due to the lack of data reported in the 394 literature, leading to a low prevalence of these types of symptoms. In the case of DCM 395 and diabetes the prevalence was the same among the established genetic groups. 396 Marshall et al., (Marshall et al., 2007b) also found a significant association between 397 alterations in exon 8 and absent, mild or delayed kidney disease; findings that were not 398 observed in our analysis.

399 The explanation for this event could be related to the residual expression of ALSM1 400 gene. Mutations in exon 10 could prevent NMD activation and give rise to a misfolded 401 protein that causes greater hepatotoxicity. In the case of mutations in exon 16 or 402 adjacent, perhaps the NMD is not activated either, but the generated protein, despite 403 not being functional, could have a semi-normal conformation that prevents the 404 formation of aggregates. This hypothesis could be easily tested if these protein isoforms 405 can be simulated by homology, but unfortunately the protein structure of the ALMS1 406 gene remains unknown and cannot be simulated using the artificial intelligence models 407 such as AlphaFold (van Breugel et al., 2022).

Finally, the *ALMS1* sequence has already described the presence of a lncRNA, *ALMS1*-409 *IT1*, with a role in regulating proliferation in various types of cancers and

neuroinflammation and a pseudo gene, *ALMS1P1*, whose function is still unknown (Lu
et al., 2021; Luan et al., 2021; Mei et al., 2021). Due to the large length of the *ALMS1*gene, the presence of more of these elements would not be uncommon and could
explain why the localisation of the cLOF variant can lead to different phenotypes. These
events could be of help understanding the regulation of *ALMS1* in the different tissues
involved in the disease, and the great heterogeneity observed for the clinical symptoms.

416 **Conclusion:**

In conclusion, 5 highly prevalent mutations were detected in our cohort. Not all of these variants appear in public databases. There are no gender differences in the prevalence of the different symptoms of ALMS. Patients' symptoms worsen with age, and the site of the *ALMS1* gene mutation does not influence the worsening of symptoms in most cases. Only truncation of the ALMS1 protein at exon 10 level correlated with a higher prevalence of liver problems in these patients.

- 423 Author Contributions: BB-M, DV designed the study. BB-M selected, reviewed, collected and
 424 curated data from the scientific articles. BB-M designed and executed the analysis pipeline. BB425 M created the publicly accessible online database. BB-M and DV drafted the article. All authors
 426 wrote the manuscript and provided approval for publication.
- Funding: This work was funded by Instituto de Salud Carlos III de Madrid FIS project PI15/00049
 and PI19/00332, Xunta de Galicia (Centro de Investigación de Galicia CINBIO 2019-2022) Ref.
 ED431G-2019/06, Consolidación e estructuración de unidades de investigación competitivas e
 outras accións de fomento (ED431C-2018/54). Brais Bea-Mascato (FPU17/01567) was
 supported by graduate studentship awards (FPU predoctoral fellowship) from the Spanish
 Ministry of Education, Culture and Sports.
- 433 Informed Consent Statement: Not Apply.
- 434 Data Availability Statement: Data are available via <u>https://github.com/BreisOne/meta-</u>
 435 <u>analysis_ALMS</u> or <u>http://genesandfunctions.uvigo.es/alms-db/</u>.
- 436 **Code Availability Statement:** The code used in this study can be consulted on the GitHub 437 repository <u>https://github.com/BreisOne/meta-analysis ALMS</u>.

438 **References:**

- Ahmad, A., D'Souza, B., Yadav, C., Agarwal, A., Kumar, A., Nandini, M., et al. (2016).
 Metabolic Syndrome in Childhood: Rare Case of Alstrom Syndrome with Blindness. *Indian J. Clin. Biochem.* 31, 480–482. doi: 10.1007/s12291-015-0543-8.
- 442 Aldahmesh, M. A., Abu-Safieh, L., Khan, A. O., Al-Hassnan, Z. N., Shaheen, R., Rajab, M.,
- et al. (2009). Allelic heterogeneity in inbred populations: The Saudi experience with
 Alström syndrome as an illustrative example. *Am. J. Med. Genet. Part A* 149, 662–
 665. doi: 10.1002/ajmg.a.32753.
- Aliferis, K., Hellé, S., Gyapay, G., Duchatelet, S., Stoetzel, C., Mandel, J. L., et al. (2012).
 Differentiating Alström from Bardet-Biedl syndrome (BBS) using systematic
 ciliopathy genes sequencing. *Ophthalmic Genet.* 33, 18–22. doi:
 10.3109/13816810.2011.620055.
- Astuti, D., Sabir, A., Fulton, P., Zatyka, M., Williams, D., Hardy, C., et al. (2017).
 Monogenic diabetes syndromes: Locus-specific databases for Alström, Wolfram,
 and Thiamine-responsive megaloblastic anemia. *Hum. Mutat.* 38, 764–777. doi:
 10.1002/humu.23233.
- Bahmad, F., Costa, C. S. A., Teixeira, M. S., de Barros Filho, J., Viana, L. M., and Marshall,
 J. (2014). Síndrome de Alström familiar: Uma rara causa de perda auditiva
 progressiva bilateral. *Braz. J. Otorhinolaryngol.* 80, 99–104. doi: 10.5935/18088694.20140023.
- Baig, S., Paisey, R., Dawson, C., Barrett, T., Maffei, P., Hodson, J., et al. (2020). Defining
 renal phenotype in Alström syndrome. *Nephrol. Dial. Transplant* 35, 994–1001. doi:
 10.1093/ndt/gfy293.
- Bakar, A. A., Kamal, N. M., Alsaedi, A., Turkistani, R., and Aldosari, D. (2017). Alström
 syndrome. *Med. (United States)* 96, 4–7. doi: 10.1097/MD.00000000006192.
- Bea-Mascato, B., Solarat, C., Perea-Romero, I., Jaijo, T., Blanco-Kelly, F., Millán, J. M., et
 al. (2021). Prevalent alms1 pathogenic variants in spanish alström patients. *Genes*(*Basel*). 12, 1–12. doi: 10.3390/genes12020282.

Benso, C., Hadjadj, E., Conrath, J., and Denis, D. (2002). Three new cases of Alström
syndrome. *Graefe's Arch. Clin. Exp. Ophthalmol.* 240, 622–627. doi:
10.1007/s00417-002-0479-6.

- 469 Boerwinkle, C., Marshall, J. D., Bryant, J., Gahl, W. A., Olivier, K. N., and Gunay-Aygun,
- 470 M. (2017). Respiratory manifestations in 38 patients with Alström syndrome.
- 471 *Pediatr. Pulmonol.* 52, 487–493. doi: https://doi.org/10.1002/ppul.23607.
- Bond, J., Flintoff, K., Higgins, J., Scott, S., Bennet, C., Parsons, J., et al. (2005). The
 importance of seeking ALMS1 mutations in infants with dilated cardiomyopathy. *J. Med. Genet.* 42, 1–3. doi: 10.1136/jmg.2004.026617.
- Braune, K., Volkmer, I., and Staege, M. S. (2017). Characterization of Alstrom Syndrome
 1 (ALMS1) Transcript Variants in Hodgkin Lymphoma Cells. *PLoS One* 12, e0170694.
- 477 Available at: https://doi.org/10.1371/journal.pone.0170694.
- Brofferio, A., Sachdev, V., Hannoush, H., Marshall, J. D., Naggert, J. K., Sidenko, S., et al.
 (2017). Characteristics of cardiomyopathy in Alström syndrome: Prospective singlecenter data on 38 patients. *Mol. Genet. Metab.* 121, 336–343. doi:
 10.1016/J.YMGME.2017.05.017.
- 482 Bronson, S. C., Anand Moses, C. R., Periyandavar, I., Dharmarajan, P., Suresh, E., 483 Shanmugam, A., et al. (2015). Diabetes in the young – A case of Alström syndrome 484 J. R. Coll. Physicians Edinb. 45, 33–37. with myopathy. doi: 485 10.4997/JRCPE.2015.108.
- Casey, J., McGettigan, P., Brosnahan, D., Curtis, E., Treacy, E., Ennis, S., et al. (2014).
 Atypical Alstrom syndrome with novel ALMS1 mutations precluded by current
 diagnostic criteria. *Eur. J. Med. Genet.* 57, 55–59. doi: 10.1016/j.ejmg.2014.01.007.
- Castro-Sánchez, S., Álvarez-Satta, M., Tohamy, M. A., Beltran, S., Derdak, S., and
 Valverde, D. (2017). Whole exome sequencing as a diagnostic tool for patients with
 ciliopathy-like phenotypes. *PLoS One* 12, 1–16. doi:
 10.1371/journal.pone.0183081.
- Catrinoiu, D., Mihai, C. M., Tuta, L., Stoicescu, R., and Simpetru, A. (2009). Rare case of
 Alstrom syndrome with empty sella and interfamilial presence of Bardet-Biedl

495 phenotype. J. Med. Life 2, 98–103.

- Chakroun, A., Ben Said, M., Ennouri, A., Achour, I., Mnif, M., Abid, M., et al. (2016). Longterm clinical follow-up and molecular testing for diagnosis of the first Tunisian
 family with Alström syndrome. *Eur. J. Med. Genet.* 59, 444–451. doi:
 10.1016/J.EJMG.2016.08.004.
- 500 Charles, S. J., Moore, A. T., Yates, J. R. W., Green, T., and Clark, P. (1990). Alstrom's 501 syndrome: Further evidence of autosomal recessive inheritance and 502 endocrinological dysfunction. J. Med. Genet. 27. 590-592. doi: 503 10.1136/jmg.27.9.590.
- 504 Chen, J.-H., Geberhiwot, T., Barrett, T. G., Paisey, R., and Semple, R. K. (2017). Refining
 505 genotype-phenotype correlation in Alström syndrome through study of primary
 506 human fibroblasts. *Mol. Genet. genomic Med.* 5, 390–404. doi: 10.1002/mgg3.296.
- 507 Collin, G. B., Marshall, J. D., Ikeda, A., So, W. V., Russell-Eggitt, I., Maffei, P., et al. (2002).
 508 Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration
 509 in Alström syndrome. *Nat. Genet.* 31, 74–8. doi: 10.1038/ng867.
- Collin, G. B., Marshall, J. D., King, B. L., Milan, G., Maffei, P., Jagger, D. J., et al. (2012).
 The Alström syndrome protein, ALMS1, interacts with α-actinin and components of
 the endosome recycling pathway. *PLoS One* 7, e37925–e37925. doi:
 10.1371/journal.pone.0037925.
- 514 Corbetti, F., Razzolini, R., Bettini, V., Marshall, J. D., Naggert, J., Tona, F., et al. (2013).
 515 Alström Syndrome: Cardiac Magnetic Resonance findings. *Int. J. Cardiol.* 167, 1257–
 516 1263. doi: 10.1016/j.ijcard.2012.03.160.

517 Cruz-Aguilar, M., Galaviz-Hernández, C., Hiebert-Froese, J., Sosa-Macías, M., and
518 Zenteno, J. C. (2017). A nonsense ALMS1 mutation underlies alström syndrome in
519 an extended mennonite kindred settled in north Mexico. *Genet. Test. Mol.*520 *Biomarkers* 21, 397–401. doi: 10.1089/gtmb.2016.0391.

521 Das Bhowmik, A., Gupta, N., Dalal, A., and Kabra, M. (2017). Whole exome sequencing 522 identifies a homozygous nonsense variation in ALMS1 gene in a patient with 523 syndromic obesity. *Obes. Res. Clin. Pract.* 11, 241–246. doi:

524 10.1016/j.orcp.2016.09.004.

- Davies, G., Lam, M., Harris, S. E., Trampush, J. W., Luciano, M., Hill, W. D., et al. (2018).
 Study of 300,486 individuals identifies 148 independent genetic loci influencing
 general cognitive function. *Nat. Commun.* 9, 2098. doi: 10.1038/s41467-01804362-x.
- 529 Dotan, G., Khetan, V., Marshall, J. D., Affel, E., Armiger-, D., Naggert, J. K., et al. (2018).
 530 Alström syndrome. 38, 440–445. doi: 10.1080/13816810.2016.1257029.Spectral531 domain.
- Fokkema, I. F. A. C., Taschner, P. E. M., Schaafsma, G. C. P., Celli, J., Laros, J. F. J., and den
 Dunnen, J. T. (2011). LOVD v.2.0: the next generation in gene variant databases. *Hum. Mutat.* 32, 557–563. doi: 10.1002/HUMU.21438.
- Gao, F. J., Li, J. K., Chen, H., Hu, F. Y., Zhang, S. H., Qi, Y. H., et al. (2019). Genetic and
 Clinical Findings in a Large Cohort of Chinese Patients with Suspected Retinitis
 Pigmentosa. *Ophthalmology* 126, 1549–1556. doi: 10.1016/j.ophtha.2019.04.038.
- Gatticchi, L., Miertus, J., Maltese, P. E., Bressan, S., De Antoni, L., Podracká, L., et al.
 (2020). A very early diagnosis of Alström syndrome by next generation sequencing. *BMC Med. Genet.* 21, 1–6. doi: 10.1186/s12881-020-01110-1.
- Gogi, D., Bond, J., Long, V., Sheridan, E., and Woods, C. G. (2007). Exudative retinopathy
 in a girl with Alström syndrome due to a novel mutation. *Br. J. Ophthalmol.* 91, 983–
 984. doi: 10.1136/bjo.2005.088781.
- Hamamy, H., Barham, M., Alkhawaldeh, A. E. K., Cockburn, D., Snowden, H., and Ajlouni,
 K. (2006). Alstrom syndrome in four sibs from northern Jordan. *Ann. Saudi Med.* 26,
 480–483. doi: 10.5144/0256-4947.2006.480.
- Hearn, T. (2018). ALMS1 and Alström syndrome: a recessive form of metabolic,
 neurosensory and cardiac deficits. *J. Mol. Med.* doi: 10.1007/s00109-018-1714-x.
- Hearn, T., Renforth, G. L., Spalluto, C., Hanley, N. A., Piper, K., Brickwood, S., et al. (2002).
 Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids,
 causes Alström syndrome. *Nat. Genet.* 31, 79. Available at:

552 https://doi.org/10.1038/ng874.

Hirano, M., Satake, W., Moriyama, N., Saida, K., Okamoto, N., Cha, P. C., et al. (2020).
Bardet–Biedl syndrome and related disorders in Japan. *J. Hum. Genet.* 65, 847–853.
doi: 10.1038/s10038-020-0778-y.

Hitz, M. P., Bertram, H., Köditz, H., Görler, H., Happel, C. M., Wessel, A., et al. (2008).
Levosimendan for bridging in a pediatric patient with Alström syndrome awaiting
heart-lung transplantation. *Clin. Res. Cardiol.* 97, 846–848. doi: 10.1007/s00392008-0691-4.

Hoffman, J. D., Jacobson, Z., Young, T. L., Marshall, J. D., and Kaplan, P. (2005). Familial
variable expression of dilated cardiomyopathy in Alström syndrome: A report of
four sibs. *Am. J. Med. Genet.* 135 A, 96–98. doi: 10.1002/ajmg.a.30688.

Holder, M., Hecker, W., and Gilli, G. (1995). Impaired glucose tolerance leads to delayed
diagnosis of Alström syndrome. *Diabetes Care* 18, 698–700. doi:
10.2337/diacare.18.5.698.

- Hollander, S. A., Alsaleh, N., Ruzhnikov, M., Jensen, K., Rosenthal, D. N., Stevenson, D.
 A., et al. (2017). Variable clinical course of identical twin neonates with Alström
 syndrome presenting coincidentally with dilated cardiomyopathy. *Am. J. Med. Genet. Part A* 173, 1687–1689. doi: 10.1002/ajmg.a.38200.
- 570 Huang, L., Xiao, X., Li, S., Jia, X., Wang, P., Sun, W., et al. (2016). Molecular genetics of 571 cone-rod dystrophy in Chinese patients: New data from 61 probands and mutation 572 overview of 163 probands. Exp. Eye Res. 146, 252-258. doi: 573 10.1016/j.exer.2016.03.015.

Hull, S., Kiray, G., Chiang, J. P. W., and Vincent, A. L. (2020). Molecular and phenotypic
investigation of a New Zealand cohort of childhood-onset retinal dystrophy. *Am. J. Med. Genet. Part C Semin. Med. Genet.* 184, 708–717. doi: 10.1002/ajmg.c.31836.

Iannello, S., Bosco, P., Camuto, M., Cavaleri, A., Milazzo, P., and Belfiore, F. (2004). A
mild form of Alstrom disease associated with metabolic syndrome and very high
fasting serum afree fatty acids: Two cases diagnosed in adult age. *Am. J. Med. Sci.*327, 284–288. doi: 10.1097/00000441-200405000-00031.

- Jatti, K., Paisey, R., and More, R. (2012). Coronary artery disease in Alström syndrome.
 Eur. J. Hum. Genet. 20, 117–118. doi: 10.1038/ejhg.2011.168.
- Jinda, W., Taylor, T. D., Suzuki, Y., Thongnoppakhun, W., Limwongse, C., Lertrit, P., et al.
 (2017). Whole exome sequencing in eight Thai patients with leber congenital
 amaurosis reveals mutations in the CTNNA1 and CYP4V2 genes. *Investig. Ophthalmol. Vis. Sci.* 58, 2413–2420. doi: 10.1167/iovs.16-21322.
- Joy, T., Cao, H., Black, G., Malik, R., Charlton-Menys, V., Hegele, R. A., et al. (2007).
 Alstrom syndrome (OMIM 203800): a case report and literature review. *Orphanet J. Rare Dis.* 2, 49. doi: 10.1186/1750-1172-2-49.
- Kamal, N. M., Sahly, A. N., Banaganapalli, B., Rashidi, O. M., Shetty, P. J., Al-Aama, J. Y.,
 et al. (2020). Whole exome sequencing identifies rare biallelic ALMS1 missense and
 stop gain mutations in familial Alström syndrome patients. *Saudi J. Biol. Sci.* 27,
 271–278. doi: 10.1016/j.sjbs.2019.09.006.
- Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., et al.
 (2020). The mutational constraint spectrum quantified from variation in 141,456
 humans. *Nat. 2020 5817809* 581, 434–443. doi: 10.1038/s41586-020-2308-7.
- Katagiri, S., Yoshitake, K., Akahori, M., Hayashi, T., Furuno, M., Nishino, J., et al. (2013).
 Whole-exome sequencing identifies a novel ALMS1 mutation (p.Q2051X) in two
 Japanese brothers with Alström syndrome. *Mol. Vis.* 19, 2393–2406. Available at:
 https://www.ncbi.nlm.nih.gov/pubmed/24319333.
- Kaya, A., Orbak, Z., Cayir, A., Doneray, H., Taşdemir, Ş., Ozanturk, A., et al. (2014).
 Combined occurrence of Alström syndrome and bronchiectasis. *Pediatrics* 133. doi:
 10.1542/peds.2013-0284.
- Kerr, T. P., Sewry, C. A., Robb, S. A., and Roberts, R. G. (2001). Long mutant dystrophins
 and variable phenotypes: evasion of nonsense-mediated decay? *Hum. Genet.* 109,
 402–407. doi: 10.1007/s004390100598.
- Khan, A. O., Bifari, I. N., and Bolz, H. J. (2015). Ophthalmic Features of Children Not Yet
 Diagnosed with Alstrom Syndrome. *Ophthalmology* 122, 1726-1727.e2. doi:
 10.1016/j.ophtha.2015.03.001.

- 610 Khoo, E. Y. H., Risley, J., Zaitoun, A. M., El-Sheikh, M., Paisey, R. B., Acheson, A. G., et al.
- 611 (2009). Alström syndrome and cecal volvulus in 2 siblings. Am. J. Med. Sci. 337, 383–
- 612 385. doi: 10.1097/MAJ.0b013e3181926594.
- 613 Kilinc, S., Yucel-Yilmaz, D., Ardagil, A., Apaydin, S., Valverde, D., Ozgul, R. K., et al. (2018).
- 614 Five novel ALMS1 gene mutations in six patients with Alstrom syndrome. *J. Pediatr.*
- 615 *Endocrinol. Metab.* 31, 681–687. doi: 10.1515/jpem-2017-0418.
- Kilpinen, H., Goncalves, A., Leha, A., Afzal, V., Alasoo, K., Ashford, S., et al. (2017).
 Common genetic variation drives molecular heterogeneity in human iPSCs. *Nature*546, 370–375. doi: 10.1038/nature22403.
- Kim, M. K., Kwak, S. H., Kang, S., Jung, H. S., Cho, Y. M., Kim, S. Y., et al. (2015).
 Identification of two cases of ciliopathy-associated diabetes and their mutation
 analysis using whole exome sequencing. *Diabetes Metab. J.* 39, 439–443. doi:
 10.4093/dmj.2015.39.5.439.
- Koç, E., Bayrak, G., Suher, M., Ensari, C., Aktas, D., and Ensari, A. (2006). Rare case of
 Alstrom syndrome without obesity and with short stature, diagnosed in adulthood. *Nephrology* 11, 81–84. doi: 10.1111/j.1440-1797.2006.00443.x.
- Kocova, M., Sukarova-Angelovska, E., Kacarska, R., Maffei, P., Milan, G., and Marshall, J.
 D. (2011). The unique combination of dermatological and ocular phenotypes in
 Alström syndrome: severe presentation, early onset and two novel ALMS1
 mutations. *Br. J. Dermatol.* 164, 878–880. doi: 10.1111/j.1365-2133.2010.10157.x.
- Koray, F., Dorter, C., Benderli, Y., Satman, I., Yilmaz, T., Dinccag, N., et al. (2001). Alstrom
 syndrome: a case report. *J. Oral Sci.* 43, 221–224. doi: 10.2334/josnusd.43.221.
- Kuburović, V., Marshall, J. D., Collin, G. B., Nykamp, K., Kuburović, N., Milenković, T., et
 al. (2013). Differences in the clinical spectrum of two adolescent male patients with
 Alström syndrome. *Clin. Dysmorphol.* 22, 7–12. doi:
 10.1097/MCD.0b013e32835b9017.
- Kvarnung, M., Taylan, F., Nilsson, D., Anderlid, B. M., Malmgren, H., LagerstedtRobinson, K., et al. (2018). Genomic screening in rare disorders: New mutations and
 phenotypes, highlighting ALG14 as a novel cause of severe intellectual disability.

639 *Clin. Genet.* 94, 528–537. doi: 10.1111/cge.13448.

- Landrum, M. J., Lee, J. M., Benson, M., Brown, G. R., Chao, C., Chitipiralla, S., et al. (2018).
 ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Res.* 46, D1062–D1067. doi: 10.1093/NAR/GKX1153.
- Laxer, C., Rahman, S. A., Sherif, M., Tahir, S., Cayir, A., Demirbilek, H., et al. (2016). A
 novel ALMS1 homozygous mutation in two Turkish brothers with Alström
 syndrome. *J. Pediatr. Endocrinol. Metab.* 29, 585–589. doi: 10.1515/jpem-20150249.
- Lazar, C. H., Kimchi, A., Namburi, P., Mutsuddi, M., Zelinger, L., Beryozkin, A., et al.
 (2015). Nonsyndromic Early-Onset Cone-Rod Dystrophy and Limb-Girdle Muscular
 Dystrophy in a Consanguineous Israeli Family are Caused by Two Independent yet
 Linked Mutations in ALMS1 and DYSF. *Hum. Mutat.* 36, 836–841. doi:
 10.1002/humu.22822.
- Lefter, M., Vis, J. K., Vermaat, M., den Dunnen, J. T., Taschner, P. E. M., and Laros, J. F. J.
 (2021). Mutalyzer 2: next generation HGVS nomenclature checker. *Bioinformatics*37, 2811–2817. doi: 10.1093/bioinformatics/btab051.
- Liang, X., Li, H., Li, H., Xu, F., Dong, F., and Sui, R. (2013). Novel ALMS1 mutations in
 Chinese patients with alström syndrome. *Mol. Vis.* 19, 1885–1891.
- Lindeboom, R. G. H., Supek, F., and Lehner, B. (2016). The rules and impact of nonsensemediated mRNA decay in human cancers. *Nat. Genet. 2016 4810* 48, 1112–1118.
 doi: 10.1038/ng.3664.
- Lindsey, S., Brewer, C., Stakhovskaya, O., Kim, H. J., Zalewski, C., Bryant, J., et al. (2017).
 Auditory and otologic profile of Alström syndrome: Comprehensive single center
 data on 38 patients. *Am. J. Med. Genet. Part A* 173, 2210–2218. doi:
 10.1002/ajmg.a.38316.
- Liu, L., Dong, B., Chen, X., Li, J., and Li, Y. (2009). Identification of a novel ALMS1 mutation
 in a Chinese family with Alström syndrome. *Eye* 23, 1210–1212. doi:
 10.1038/eye.2008.235.

Lombardo, B., D'Argenio, V., Monda, E., Vitale, A., Caiazza, M., Sacchetti, L., et al. (2020).
Genetic analysis resolves differential diagnosis of a familial syndromic dilated
cardiomyopathy: A new case of Alström syndrome. *Mol. Genet. Genomic Med.* 8,
1–7. doi: 10.1002/mgg3.1260.

- Long, P. A., Evans, J. M., Olson, T. M., Gartstein., M. A., Putnam., S., and Kliewer., R.
 (2015). Exome sequencing establishes diagnosis of Alström syndrome in an infant
 presenting with non-syndromic dilated cardiomyopathy. *Am. J. Med. Genet. A* 176,
 886–890. doi: 10.1002/ajmg.a.36994.Exome.
- Louw, J. J., Corveleyn, A., Jia, Y., Iqbal, S., Boshoff, D., Gewillig, M., et al. (2014).
 Homozygous loss-of-function mutation in ALMS1 causes the lethal disorder
 mitogenic cardiomyopathy in two siblings. *Eur. J. Med. Genet.* 57, 532–535. doi:
 10.1016/j.ejmg.2014.06.004.
- Lu, P., Zhang, Y., Niu, H., and Wang, Y. (2021). Upregulated Long Non-coding RNA
 ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic
 Cerebral Injury. *Curr. Pharm. Des.* 27, 4270–4277. doi:
 10.2174/1381612827666210827104316.
- Luan, T., Zhang, T. Y., Lv, Z. H., Guan, B. X., Xu, J. Y., Li, J., et al. (2021). The lncRNA ALMS1IT1 may promote malignant progression of lung adenocarcinoma via AVL9mediated activation of the cyclin-dependent kinase pathway. *FEBS Open Bio* 11,
 1504–1515. doi: 10.1002/2211-5463.13140.
- Mahamid, J., Lorber, A., Horovitz, Y., Shalev, S. A., Collin, G. B., Naggert, J. K., et al. (2013).
 Extreme clinical variability of dilated cardiomyopathy in two siblings with alström
 syndrome. *Pediatr. Cardiol.* 34, 455–458. doi: 10.1007/s00246-012-0296-6.
- Malm, E., Ponjavic, V., Nishina, P. M., Naggert, J. K., Hinman, E. G., Andréasson, S., et al.
 (2008). Full-field electroretinography and marked variability in clinical phenotype
 of Alström syndrome. *Arch. Ophthalmol.* 126, 51–57. doi:
 10.1001/archophthalmol.2007.28.
- Maltese, P. E., Iarossi, G., Ziccardi, L., Colombo, L., Buzzonetti, L., Crinò, A., et al. (2018).
 A Next Generation Sequencing custom gene panel as first line diagnostic tool for

- 696 atypical cases of syndromic obesity: Application in a case of Alström syndrome. *Eur.*
- 697 *J. Med. Genet.* 61, 79–83. doi: 10.1016/j.ejmg.2017.10.016.
- Marshall, J. D., Beck, S., Maffei, P., and Naggert, J. K. (2007a). Alström Syndrome. *Eur. J. Hum. Genet.* 15, 1193. doi: 10.1038/sj.ejhg.5201933.
- Marshall, J. D., Bronson, R. T., Collin, G. B., Nordstrom, A. D., Maffei, P., Paisey, R. B., et
 al. (2005). New Alström syndrome phenotypes based on the evaluation of 182
 cases. *Arch. Intern. Med.* 165, 675–83. doi: 10.1001/archinte.165.6.675.
- Marshall, J. D., Hinman, E. G., Collin, G. B., Beck, S., Cerqueira, R., Maffei, P., et al.
 (2007b). Spectrum of ALMS1 variants and evaluation of genotype-phenotype
 correlations in Alström syndrome. *Hum. Mutat.* 28, 1114–23. doi:
 10.1002/humu.20577.
- Marshall, J. D., Maffei, P., Collin, G. B., and Naggert, J. K. (2011). Alström syndrome:
 genetics and clinical overview. *Curr. Genomics* 12, 225–235. doi:
 10.2174/138920211795677912.
- Marshall, J. D., Muller, J., Collin, G. B., Milan, G., Kingsmore, S. F., Dinwiddie, D., et al.
 (2015). Alström Syndrome: Mutation Spectrum of ALMS1. *Hum. Mutat.* 36, 660–
 668. doi: 10.1002/humu.22796.
- Mauring, L., Porter, L. F., Pelletier, V., Riehm, A., Leuvrey, A. S., Gouronc, A., et al. (2020).
 Atypical Retinal Phenotype in a Patient With Alström Syndrome and Biallelic Novel
 Pathogenic Variants in ALMS1, Including a de novo Variation. *Front. Genet.* 11. doi:
 10.3389/fgene.2020.00938.
- Mei, J., Cao, G., He, H., Chang, J., Zhang, B., and Mei, Y. (2021). Effects of long non-coding
 RNA ALMS1-IT1 on the proliferation and migration of colorectal cancer cells via
 regulating the expressions of miRNA-889-3p and ATAD2. *Cancer Res. Clin.* 33, 818–
 823. doi: 10.3760/CMA.J.CN115355-20210601-00242.
- Millay, R. H., Weleber, R. G., and Heckenlively, J. R. (1986). Ophthalmologic and systemic
 manifestations of Alström's disease. *Am. J. Ophthalmol.* 102, 482–490. doi:
 10.1016/0002-9394(86)90078-4.

724 Minton, J. A. L., Owen, K. R., Ricketts, C. J., Crabtree, N., Shaikh, G., Ehtisham, S., et al.

725 (2006). Syndromic obesity and diabetes: Changes in body composition with age and

726 mutation analysis of ALMS1 in 12 United Kingdom kindreds with Alström syndrome.

727 *J. Clin. Endocrinol. Metab.* 91, 3110–3116. doi: 10.1210/jc.2005-2633.

Nasser, F., Weisschuh, N., Maffei, P., Milan, G., Heller, C., Zrenner, E., et al. (2018).
Ophthalmic features of cone-rod dystrophy caused by pathogenic variants in the
ALMS1 gene. *Acta Ophthalmol.* 96, e445–e454. doi: 10.1111/aos.13612.

- Niederlova, V., Modrak, M., Tsyklauri, O., Huranova, M., and Stepanek, O. (2019). Metaanalysis of genotype-phenotype associations in Bardet-Biedl syndrome uncovers
 differences among causative genes. *Hum. Mutat.* 40, 2068–2087. doi:
 10.1002/HUMU.23862.
- Nikopoulos, K., Butt, G. U., Farinelli, P., Mudassar, M., Domènech-Estévez, E., Samara,
 C., et al. (2016). A large multiexonic genomic deletion within the ALMS1 gene
 causes Alström syndrome in a consanguineous Pakistani family. *Clin. Genet.* 89,
 510–511. doi: 10.1111/cge.12645.
- Ozantürk, A., Marshall, J. D., Collin, G. B., Düzenli, S., Marshall, R. P., Candan, Ş., et al.
 (2014). The phenotypic and molecular genetic spectrum of Alström syndrome in 44
 Turkish kindreds and a literature review of Alström syndrome in Turkey. *J. Hum. Genet.* 60, 1–9. doi: 10.1038/jhg.2014.85.
- Özgül, R. K., Satman, I., Collin, G. B., Hinman, E. G., Marshall, J. D., Kocaman, O., et al.
 (2007). Molecular analysis and long-term clinical evaluation of three siblings with
 Alström syndrome. *Clin. Genet.* 72, 351–356. doi: 10.1111/j.13990004.2007.00848.x.
- Paisey, R. B., Carey, C. M., Bower, L., Marshall, J., Taylor, P., Maffei, P., et al. (2004).
 Hypertriglyceridaemia in Alström's syndrome: Causes and associations in 37 cases. *Clin. Endocrinol. (Oxf).* 60, 228–231. doi: 10.1111/j.1365-2265.2004.01952.x.
- Patel, S., Minton, J. A. L., Weedon, M. N., Frayling, T. M., Ricketts, C., Hitman, G. A., et
 al. (2006). Common variations in the ALMS1 gene do not contribute to susceptibility
 to type 2 diabetes in a large white UK population. *Diabetologia* 49, 1209–1213. doi:

753 10.1007/s00125-006-0227-2.

Piñeiro-Gallego, T., Cortón, M., Ayuso, C., Baiget, M., and Valverde, D. (2012). Molecular
approach in the study of Alström syndrome: analysis of ten Spanish families. *Mol. Vis.* 18, 1794–1802. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/22876109.

758 Redin, C., Le Gras, S., Mhamdi, O., Geoffroy, V., Stoetzel, C., Vincent, M. C., et al. (2012).

Targeted high-throughput sequencing for diagnosis of genetically heterogeneous
diseases: Efficient mutation detection in Bardet-Biedl and Alström Syndromes. J.
Med. Genet. 49, 502–512. doi: 10.1136/jmedgenet-2012-100875.

Rethanavelu, K., Fung, J. L. F., Chau, J. F. T., Pei, S. L. C., Chung, C. C. Y., Mak, C. C. Y., et
al. (2020). Phenotypic and mutational spectrum of 21 Chinese patients with
Alström syndrome. *Am. J. Med. Genet. Part A* 182, 279–288. doi:
10.1002/ajmg.a.61412.

Russell-Eggitt, I. M., Clayton, P. T., Coffey, R., Kriss, A., Taylor, D. S. I., and Taylor, J. F. N.
(1998). Alstrom syndrome: Report of 22 cases and literature review. *Ophthalmology* 105, 1274–1280. doi: 10.1016/S0161-6420(98)97033-6.

Saadah, O. I., Banaganapalli, B., Kamal, N. M., Sahly, A. N., Alsufyani, H. A., Mohammed,
A., et al. (2021). Identification of a Rare Exon 19 Skipping Mutation in ALMS1 Gene
in Alström Syndrome Patients From Two Unrelated Saudi Families. *Front. Pediatr.*9, 1–9. doi: 10.3389/fped.2021.652011.

Sanchez-Navarro, I., R. J. da Silva, L., Blanco-Kelly, F., Zurita, O., Sanchez-Bolivar, N.,
Villaverde, C., et al. (2018). Combining targeted panel-based resequencing and
copy-number variation analysis for the diagnosis of inherited syndromic
retinopathies and associated ciliopathies. *Sci. Rep.* 8, 5285. doi: 10.1038/s41598018-23520-1.

Sanyoura, M., Woudstra, C., Halaby, G., Baz, P., Senée, V., Guillausseau, P. J., et al.
(2014). A novel ALMS1 splice mutation in a non-obese juvenile-onset insulindependent syndromic diabetic patient. *Eur. J. Hum. Genet.* 22, 140–143. doi:
10.1038/ejhg.2013.87.

782 Sathya Priya, C., Sen, P., Umashankar, V., Gupta, N., Kabra, M., Kumaramanickavel, G.,

et al. (2015). Mutation spectrum in BBS genes guided by homozygosity mapping in
an Indian cohort. *Clin. Genet.* 87, 161–166. doi: 10.1111/cge.12342.

- Satman, I., Yilmaz, M. T., Gürsoy, N., Karşidağ, K., Dinççağ, N., Ovali, T., et al. (2002).
 Evaluation of insulin resistant diabetes mellitus in Alström syndrome: A long-term
 prospective follow-up of three siblings. *Diabetes Res. Clin. Pract.* 56, 189–196. doi:
 10.1016/S0168-8227(02)00004-9.
- Sawyer, S. L., Hartley, T., Dyment, D. A., Beaulieu, C. L., Schwartzentruber, J., Smith, A.,
 et al. (2016). Utility of whole-exome sequencing for those near the end of the
 diagnostic odyssey: time to address gaps in care. *Clin. Genet.* 89, 275–284. doi:
 10.1111/CGE.12654.
- Shurygina, M. F., Parker, M. A., Schlechter, C. L., Chen, R., Li, Y., Weleber, R. G., et al.
 (2019). A case report of two siblings with Alstrom syndrome without hearing loss
 associated with two new ALMS1 variants. *BMC Ophthalmol.* 19, 1–9. doi:
 10.1186/s12886-019-1259-y.
- Silan, F., Gur, S., Kadioglu, L. E., Yalcintepe, S. A., Ukinc, K., Uludag, A., et al. (2013).
 Characteristic findings of alstrom syndrome with a case report. *Open J. Clin. Diagnostics* 03, 75–77. doi: 10.4236/ojcd.2013.33014.
- Spinelli, V., Girolami, F., Marrone, C., Consigli, V., Iascone, M., Passantino, S., et al.
 (2020). A rare case of pediatric cardiomyopathy: Alström syndrome identified by
 gene panel analysis. *Clin. Case Reports* 8, 3369–3373. doi: 10.1002/ccr3.3327.
- Srikrupa, N. N., Sripriya, S., Pavithra, S., Sen, P., Gupta, R., and Mathavan, S. (2021).
 Whole-exome sequencing identifies two novel ALMS1 mutations in Indian patients
 with Leber congenital amaurosis. *Hum. Genome Var.* 8. doi: 10.1038/s41439-02100143-z.
- Supek, F., Lehner, B., and Lindeboom, R. G. H. (2021). To NMD or Not To NMD:
 Nonsense-Mediated mRNA Decay in Cancer and Other Genetic Diseases. *Trends Genet.* 37, 657–668. doi: 10.1016/J.TIG.2020.11.002.
- 810 Taokesen, M., Collin, G. B., Evsikov, A. V., Güzel, A., Özgül, R. K., Marshall, J. D., et al.

811 (2012). Novel Alu retrotransposon insertion leading to Alström syndrome. *Hum.*

812 *Genet.* 131, 407–413. doi: 10.1007/s00439-011-1083-9.

- Taşdemir, S., Güzel-Ozantürk, A., Marshall, J., Collin, G., Özgül, R., Narin, N., et al. (2013).
 Atypical presentation and a novel mutation in ALMS1: implications for clinical and
 molecular diagnostic strategies for Alström syndrome. *Clin. Genet.* 83, 96–98. doi:
 10.1111/J.1399-0004.2012.01883.X.
- Titomanlio, L., De Brasi, D., Buoninconti, A., Sperandeo, M. P., Pepe, A., Andria, G., et al.
 (2004). Alström syndrome: Intrafamilial phenotypic variability in sibs with a novel
 nonsense mutation of the ALMS1 gene [3]. *Clin. Genet.* 65, 156–157. doi:
 10.1111/j.0009-9163.2004.00204.x.

821 Torkamandi, S., Rezaei, S., Mirfakhraei, R., Askari, M., Piltan, S., and Gholami, M. (2020). 822 Whole exome sequencing identified two homozygous ALMS1 mutations in an 823 family Alström syndrome. Iranian with Gene 727, 144228. doi: 10.1016/j.gene.2019.144228. 824

- Tsai, M. C., Yu, H. W., Liu, T., Chou, Y. Y., Chiou, Y. Y., and Chen, P. C. (2018). Rare
 compound heterozygous frameshift mutations in ALMS1 gene identified through
 exome sequencing in a Taiwanese patient with Alström syndrome. *Front. Genet.* 9,
 1–5. doi: 10.3389/fgene.2018.00110.
- van Breugel, M., Rosa e Silva, I., and Andreeva, A. (2022). Structural validation and
 assessment of AlphaFold2 predictions for centrosomal and centriolar proteins and
 their complexes. *Commun. Biol.* 5, 1–10. doi: 10.1038/s42003-022-03269-0.

Waldman, M., Han, J. C., Reyes-Capo, D. P., Bryant, J., Carson, K. A., Turkbey, B., et al.
(2018). Alström syndrome: Renal findings in correlation with obesity, insulin
resistance, dyslipidemia and cardiomyopathy in 38 patients prospectively
evaluated at the NIH clinical center. *Mol. Genet. Metab.* 125, 181–191. doi:
10.1016/j.ymgme.2018.07.010.

Wang, C., Luo, X., Wang, Y., Liu, Z., Wu, S., Wang, S., et al. (2021). Novel mutations of
the ALMS1 gene in patients with alström syndrome. *Intern. Med.* 60, 3721–3728.
doi: 10.2169/internalmedicine.6467-20.

- Wang, S., Zhang, Q., Zhang, X., Wang, Z., and Zhao, P. (2016a). Clinical and genetic
 characteristics of Leber congenital amaurosis with novel mutations in known genes
 based on a Chinese eastern coast Han population. *Graefe's Arch. Clin. Exp. Ophthalmol.* 254, 2227–2238. doi: 10.1007/s00417-016-3428-5.
- Wang, X., Feng, Y., Li, J., Zhang, W., Wang, J., Lewis, R. A., et al. (2016b). Retinal diseases
 caused by mutations in genes not specifically associated with the clinical diagnosis.
- 846 *PLoS One* 11, 1–12. doi: 10.1371/journal.pone.0165405.
- Wang, X., Wang, H., Cao, M., Li, Z., Chen, X., Patenia, C., et al. (2011). Whole-exome
 sequencing identifies ALMS1, IQCB1, CNGA3, and MYO7A mutations in patients
 with Leber congenital amaurosis. *Hum. Mutat.* 32, 1450–1459. doi:
 10.1002/humu.21587.
- Weiss, S., Cohen, L., Ben-Yosef, T., Ehrenberg, M., and Goldenberg-Cohen, N. (2019).
 Late diagnosis of Alstrom syndrome in a Yemenite-Jewish child. *Ophthalmic Genet*.
 40, 7–11. doi: 10.1080/13816810.2018.1561900.
- Wicher, K., Bajon, T., Wawrocka, A., Skorczyk-Werner, A., Niedziela, M., and
 Krawczynski, M. R. (2017). Alström syndrome: A case report of the Polish family and
 a brief review of the differential diagnosis. *Pediatr. Pol.* 92, 781–785. doi:
 10.1016/j.pepo.2017.07.003.
- Worthley, M. I., and Zeitz, C. J. (2001). Case of Alstrim syndrome with late presentation
 dilated cardiomyopathy. *Intern. Med. J.* 31, 569–570. doi: 10.1046/j.14455994.2001.00140.x.
- Wu, W. C., Chen, S. C., Dia, C. Y., Yu, M. L., Hsieh, M. Y., Lin, Z. Y., et al. (2003). Alström
 syndrome with acute pancreatitis: A case report. *Kaohsiung J. Med. Sci.* 19, 358–
 360. doi: 10.1016/s1607-551x(09)70438-3.
- Xu, Y., Guan, L., Xiao, X., Zhang, J., Li, S., Jiang, H., et al. (2016). ALMS1 null mutations: A
 common cause of Leber congenital amaurosis and early-onset severe cone-rod
 dystrophy. *Clin. Genet.* 89, 442–447. doi: 10.1111/cge.12617.
- Yang, L., Li, Z., Mei, M., Fan, X., Zhan, G., Wang, H., et al. (2017). Whole genome
 sequencing identifies a novel ALMS1 gene mutation in two Chinese siblings with

Alström syndrome. *BMC Med. Genet.* 18, 1–6. doi: 10.1186/s12881-017-0418-3.

- Zhang, J. J., Wang, J. Q., Sun, M. Q., Xu, D., Xiao, Y., Lu, W. L., et al. (2021). Alström
 syndrome with a novel mutation of ALMS1 and Graves' hyperthyroidism: A case
 report and review of the literature. *World J. Clin. Cases* 9, 3200–3211. doi:
 10.12998/wjcc.v9.i13.3200.
- Zhou, C., Xiao, Y., Xie, H., Liu, S., and Wang, J. (2020). A novel variant in ALMS1 in a
 patient with Alström syndrome and prenatal diagnosis for the fetus in the family: A
 case report and literature review. *Mol. Med. Rep.* 22, 3271–3276. doi:
 10.3892/mmr.2020.11398.
- 878 Zmyslowska, A., Borowiec, M., Antosik, K., Ploski, R., Ciechanowska, M., Iwaniszewska,
- 879 B., et al. (2016). Genetic evaluation of patients with Alström syndrome in the Polish
- 880 population. *Clin. Genet.* 89, 448–453. doi: 10.1111/cge.12656.

881





